E
Incannex Healthcare Inc. IXHL
$0.1327 -$0.0002-0.15% NASDAQ
Recommendation
Prev Close
$0.1329
Volume
3,927,546
Avg Vol (90D)
436,819
Market Cap
$3.66M
Dividend & Yield
--
52-Week Range
$0.1264 - $3.55
P/E (TTM)
--
EPS (TTM)
-$1.40
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral ...
4/3/2025 - GuruFocus
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
4/3/2025 - Globe Newswire
Incannex Healthcare files to sell 65.97M shares of common stock for holders
3/24/2025 - SeekingAlpha.com: All News
Incannex Healthcare Inc. Announces Pricing of $12. ...
3/7/2025 - GuruFocus
Incannex Healthcare prices $12.5M private placement
3/7/2025 - Seeking Alpha - Healthcare
Incannex Healthcare prices $12.5M private placement
3/7/2025 - SeekingAlpha.com: All News
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
3/7/2025 - Globe Newswire
Incannex Healthcare Limited Reports Quarterly Financials
2/19/2025 - TipRanks Financial Blog
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
2/18/2025 - Newsfile Corp. - News Releases
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
2/14/2025 - GuruFocus
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
2/14/2025 - Globe Newswire
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Growth in Short Interest
2/12/2025 - Ticker Report
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
2/4/2025 - Globe Newswire
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of ...
1/23/2025 - GuruFocus
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
1/23/2025 - Globe Newswire
Incannex Healthcare Inc. Receives Notice of Listing Deficiency from NasdaqOn January 3, 2025, Incannex Healthcare Inc. (NASDAQ: IXHL) received a written notice from The Nasdaq Stock Market LLC stating that the company is not in compliance with Nasdaq
1/13/2025 - Ticker Report
Critical Survey: Incannex Healthcare (NASDAQ:IXHL) versus Alterity Therapeutics (NASDAQ:ATHE)
1/13/2025 - Ticker Report
Critical Survey: Incannex Healthcare (NASDAQ:IXHL) vs. TFF Pharmaceuticals (NASDAQ:TFFP)
12/4/2024 - Ticker Report
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
12/2/2024 - Newsfile Corp. - News Releases
Incannex Healthcare (NASDAQ:IXHL) Shares Up 5.5% - Still a Buy?
11/19/2024 - MarketBeat
Incannex Healthcare Reports Q3 Loss, Secures New Funding
11/19/2024 - TipRanks Financial Blog
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
11/14/2024 - Globe Newswire
Incannex appoints Barbato as Chief Medical Officer
10/24/2024 - TipRanks Financial Blog
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
10/24/2024 - Globe Newswire
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks
10/22/2024 - Simply Wall St
Income Statement
Total Revenue (TTM)
$98.00K
EBITDA (TTM)
-$21.78M
EBIT (TTM)
-$22.05M
Net Income (TTM)
-$23.81M
Balance Sheet
Total Assets (Q)
$11.11M
Total Debt (Q)
$4.10M
Total Liabilities (Q)
$10.14M
Book Value Per Share (Q)
$0.0543
Cash Flow
Cash from Operations (TTM)
-$15.87M
Cash from Investing (TTM)
-$5.00K
Cash from Financing (TTM)
$4.05M
Net Change in Cash (TTM)
-$12.46M
Filings
Filing Date
Friday, February 14, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.80
7-Day Total Return
-77.51%
30-Day Total Return
-84.26%
60-Day Total Return
-94.00%
90-Day Total Return
-92.57%
Year to Date Total Return
-93.41%
1-Year Total Return
-94.80%
2-Year Total Return
-98.30%
3-Year Total Return
-99.51%
5-Year Total Return
--
52-week Low
Apr 30, 2025 - $0.1264
52-week High
Jun 21, 2024 - $3.55
Valuation
Market Cap
$3.66M - Nano Cap
Enterprise Value
$5.66M
Price/Sales (TTM)
24.16
Price/Book (Q)
2.45
Dividends and Shares
Shares Outstanding
17.62M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.incannex.com
Phone Number
61 4 0984 0786
Address
8 Century Circuit
Suite 105 - Norwest
Sydney, NSW 2153
Country
Australia
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients... more
NASDAQ 05/02/2025 4:00PM Eastern Quotes delayed